Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 270, Boston, MA 02114-2696.
Institute for Diagnostic and Interventional Radiology, University Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
AJR Am J Roentgenol. 2022 Oct;219(4):614-623. doi: 10.2214/AJR.21.27272. Epub 2022 Apr 20.
Prior studies have provided mixed results for the ability to replace true unenhanced (TUE) images with virtual unenhanced (VUE) images when characterizing renal lesions by dual-energy CT (DECT). Detector-based dual-layer DECT (dlDECT) systems may optimize performance of VUE images for this purpose. The purpose of this article was to compare dual-phase dlDECT examinations evaluated using VUE and TUE images in differentiating cystic and solid renal masses. This retrospective study included 110 patients (mean age, 64.3 ± 11.8 years; 46 women, 64 men) who underwent renal-mass protocol dlDECT between July 2018 and February 2022. TUE, VUE, and nephrographic phase image sets were reconstructed. Lesions were diagnosed as solid masses by histopathology or MRI. Lesions were diagnosed as cysts by composite criteria reflecting findings from MRI, ultrasound, and the TUE and nephrographic phase images of the dlDECT examinations. One radiologist measured lesions' attenuation on all dlDECT image sets. Lesion characterization was compared between use of VUE and TUE images, including when considering enhancement of 20 HU or greater to indicate presence of a solid mass. The analysis included 219 lesions (33 solid masses; 186 cysts [132 simple, 20 septate, 34 hyperattenuating]). TUE and VUE attenuation were significantly different for solid masses (33.4 ± 7.1 HU vs 35.4 ± 8.6 HU, = .002), simple cysts (10.8 ± 5.6 HU vs 7.1 ± 8.1 HU, < .001), and hyperattenuating cysts (56.3 ± 21.0 HU vs 47.6 ± 16.3 HU, < .001), but not septate cysts (13.6 ± 8.1 HU vs 14.0 ± 6.8 HU, = .79). Frequency of enhancement 20 HU or greater when using TUE and VUE images was 90.9% and 90.9% in solid masses, 0.0% and 9.1% in simple cysts, 15.0% and 10.0% in septate cysts, and 11.8% and 38.2% in hyperattenuating cysts. All solid lesions were concordant in terms of enhancement 20 HU or greater when using TUE and VUE images. Twelve simple cysts and nine hyperattenuating cysts showed enhancement of 20 HU or greater when using VUE but not TUE images. Use of VUE images reliably detected enhancement in solid masses. However, VUE images underestimated attenuation of simple and hyperattenuating cysts, leading to false-positive findings of enhancement by such lesions. The findings do not support replacement of TUE acquisitions with VUE images when characterizing renal lesions by dlDECT.
先前的研究对于在使用双能 CT (DECT) 描述肾脏病变时,用虚拟平扫 (VUE) 图像替代真实平扫 (TUE) 图像的能力提供了混合结果。基于探测器的双层 DECT (dlDECT) 系统可能会优化 VUE 图像的性能以达到此目的。本文的目的是比较使用 VUE 和 TUE 图像在区分囊性和实性肾脏肿块方面的双期 dlDECT 检查结果。本回顾性研究纳入了 110 名患者(平均年龄 64.3 ± 11.8 岁;女性 46 名,男性 64 名),他们在 2018 年 7 月至 2022 年 2 月间接受了肾脏肿块协议 dlDECT 检查。重建了 TUE、VUE 和肾实质期图像集。通过组织病理学或 MRI 诊断实性肿块。通过反映 MRI、超声和 dlDECT 检查的 TUE 和肾实质期图像结果的综合标准诊断为囊肿。一位放射科医生在所有 dlDECT 图像集上测量了病变的衰减。比较了使用 VUE 和 TUE 图像进行病变特征描述的结果,包括当增强 20HU 或以上被认为存在实性肿块时。该分析包括 219 个病变(33 个实性肿块;186 个囊肿[132 个单纯性,20 个分隔性,34 个高增强性])。TUE 和 VUE 衰减在实性肿块(33.4 ± 7.1HU 与 35.4 ± 8.6HU,< 0.002)、单纯性囊肿(10.8 ± 5.6HU 与 7.1 ± 8.1HU,< 0.001)和高增强性囊肿(56.3 ± 21.0HU 与 47.6 ± 16.3HU,< 0.001)之间有显著差异,但在分隔性囊肿(13.6 ± 8.1HU 与 14.0 ± 6.8HU,= 0.79)之间没有差异。当使用 TUE 和 VUE 图像时,增强 20HU 或以上的实性肿块的频率分别为 90.9%和 90.9%,单纯性囊肿分别为 0.0%和 9.1%,分隔性囊肿分别为 15.0%和 10.0%,高增强性囊肿分别为 11.8%和 38.2%。当使用 TUE 和 VUE 图像时,所有实性病变在增强 20HU 或以上方面都是一致的。12 个单纯性囊肿和 9 个高增强性囊肿在使用 VUE 但不使用 TUE 图像时显示增强 20HU 或以上。VUE 图像可靠地检测到实性肿块的增强。然而,VUE 图像低估了单纯性和高增强性囊肿的衰减,导致这些病变的增强出现假阳性结果。这些发现不支持在使用 dlDECT 描述肾脏病变时用 VUE 图像替代 TUE 采集。